Global Kidney Cancer Drugs Market Growth 2025-2031
Description
The global Kidney Cancer Drugs market size is predicted to grow from US$ 4511 million in 2025 to US$ 5861 million in 2031; it is expected to grow at a CAGR of 4.5% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Kidney cancer, also known as renal cancer, is a type of cancer that starts in the cells in the kidney. The two most common types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) of the renal pelvis. These names reflect the type of cell from which the cancer developed. The different types of kidney cancer (such as RCC and TCC) develop in different ways, meaning that the diseases have different long term outcomes, and need to be staged and treated in different ways. RCC is responsible for approximately 80% of primary renal cancers, and TCC accounts the majority of the remainder.
Biological therapies are drugs which are used to kill cancer cells or stop them from growing. Biological therapies are used to try to shrink or control advanced kidney cancer and help people to live longer. You may be given biological therapies for kidney cancer that has already spread, or is at high-risk of coming back after surgery.
LP Information, Inc. (LPI) ' newest research report, the “Kidney Cancer Drugs Industry Forecast” looks at past sales and reviews total world Kidney Cancer Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Kidney Cancer Drugs sales for 2025 through 2031. With Kidney Cancer Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Kidney Cancer Drugs industry.
This Insight Report provides a comprehensive analysis of the global Kidney Cancer Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Kidney Cancer Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Kidney Cancer Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Kidney Cancer Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Kidney Cancer Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Kidney Cancer Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Angiogenesis Inhibitors
mTOR Inhibitors
Monoclonal Antibodies
Cytokine Immunotherapy (IL-2)
Segmentation by Application:
Renal Cell Carcinoma (RCC)
Transitional Cell Carcinoma (TCC)
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Bayer
Roche
GlaxoSmithKline
Novartis
Pfizer
Abbott Laboratories
Active Biotech
Amgen
Argos Therapeutics
ArQule
AVEO Pharmaceuticals
Bionomics
Bristol-Myers Squibb
Cerulean Pharma
Exelixis
Genentech
immatics biotechnologies
Immunicum
Ono Pharmaceutical
Onyx Therapeutics
Oxford BioMedica
Prometheus Laboratories
Seattle Genetics
Taiwan Liposome
Tracon Pharmaceuticals
Wilex
Key Questions Addressed in this Report
What is the 10-year outlook for the global Kidney Cancer Drugs market?
What factors are driving Kidney Cancer Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Kidney Cancer Drugs market opportunities vary by end market size?
How does Kidney Cancer Drugs break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Kidney cancer, also known as renal cancer, is a type of cancer that starts in the cells in the kidney. The two most common types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) of the renal pelvis. These names reflect the type of cell from which the cancer developed. The different types of kidney cancer (such as RCC and TCC) develop in different ways, meaning that the diseases have different long term outcomes, and need to be staged and treated in different ways. RCC is responsible for approximately 80% of primary renal cancers, and TCC accounts the majority of the remainder.
Biological therapies are drugs which are used to kill cancer cells or stop them from growing. Biological therapies are used to try to shrink or control advanced kidney cancer and help people to live longer. You may be given biological therapies for kidney cancer that has already spread, or is at high-risk of coming back after surgery.
LP Information, Inc. (LPI) ' newest research report, the “Kidney Cancer Drugs Industry Forecast” looks at past sales and reviews total world Kidney Cancer Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Kidney Cancer Drugs sales for 2025 through 2031. With Kidney Cancer Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Kidney Cancer Drugs industry.
This Insight Report provides a comprehensive analysis of the global Kidney Cancer Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Kidney Cancer Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Kidney Cancer Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Kidney Cancer Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Kidney Cancer Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Kidney Cancer Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Angiogenesis Inhibitors
mTOR Inhibitors
Monoclonal Antibodies
Cytokine Immunotherapy (IL-2)
Segmentation by Application:
Renal Cell Carcinoma (RCC)
Transitional Cell Carcinoma (TCC)
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Bayer
Roche
GlaxoSmithKline
Novartis
Pfizer
Abbott Laboratories
Active Biotech
Amgen
Argos Therapeutics
ArQule
AVEO Pharmaceuticals
Bionomics
Bristol-Myers Squibb
Cerulean Pharma
Exelixis
Genentech
immatics biotechnologies
Immunicum
Ono Pharmaceutical
Onyx Therapeutics
Oxford BioMedica
Prometheus Laboratories
Seattle Genetics
Taiwan Liposome
Tracon Pharmaceuticals
Wilex
Key Questions Addressed in this Report
What is the 10-year outlook for the global Kidney Cancer Drugs market?
What factors are driving Kidney Cancer Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Kidney Cancer Drugs market opportunities vary by end market size?
How does Kidney Cancer Drugs break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
184 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Kidney Cancer Drugs by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Kidney Cancer Drugs by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
